Mircera positive on Haemoglobin Levels in kidney patients on dialysis

A new Roche Phase III analysis has showned that once-monthly MIRCERA, which is in fact a continuous erythropoietin receptor activator, does effectively treats renal anaemia in one of the fastest growing groups of patients suffering from chronic kidney disease.

The results of the research conducted have indicated that intravenous and subcutaneous MIRCERA maintained stable Hb levels in dialysis patients suffering from Kidney diseases that were over and under 65 years of age who were successfully switched from the frequently administered agents, epoetin alfa and beta.